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A B S T R A C T
Background: Cigarette smoking and depression are major public health concerns, but longitudinal research on
the association between smoking and antidepressant use is scarce. The purpose of this study was to investigate,
whether smoking predicts antidepressant medication during a 10-year follow-up.
Methods: A questionnaire was administered to Finnish adult twins in 1990. Antidepressant prescription data
during 1995–2004 were obtained from the register of the Finnish Social Insurance Institution and linked to the
survey data. Cox Proportional Hazard Models among 10,652 individuals (1075 cases, 9577 controls) assessed
the risk for depression in the cohort, whereas within-pair comparisons of smoking twins with their non-smoking
co-twins controlled for shared familial inﬂuences.
Results: Daily smokers had a signiﬁcantly elevated likelihood for having antidepressant prescriptions in the
follow-up. Based on the analysis among those without baseline depression, heavy daily smokers had a
signiﬁcantly elevated likelihood (HR 1.56, 95% CI 1.17–2.08) for antidepressant prescription when adjusted for
all confounders. Similar analysis using pairs discordant for antidepressant medication conﬁrmed that daily
smoking twins had a higher likelihood for prescriptions (HR 1.98, 95% CI 1.11–3.54) compared with their non-
smoking co-twins. The estimates were for MZ pairs (HR 1.78, 95% CI 0.48–6.55) and DZ pairs (HR 1.92, 95%
CI 0.99–3.72), respectively.
Limitations: Changes in smoking status after baseline cannot be accounted for. Reversed association between
depression and smoking cannot be ruled out.
Conclusion: Daily smoking predicts antidepressant medication, even when controlling for essential confoun-
ders and familial factors. This study highlights the need of systematically assessing depressive symptoms among
smokers.
1. Introduction
Smoking and depression are major public health concerns (Royal
College of Psychiatrists, 2013; World Health Organization, 2013).
Depression is common and poses a substantial burden both societally,
economically and individually (Kessler and Bromet, 2013; World
Health Organization, 2012). Daily smoking is reported among 19% of
men and 13% of women in Finland (Helldan et al., 2013) and the
prevalence of nicotine dependence among Finnish ever smokers is very
high (48–52%) (Broms et al., 2012).
The nature of this association between smoking behavior, nicotine
dependence and depression can be discussed under various scenarios
(Fluharty et al., 2016). First, the association may be causal between
smoking and depression and that cigarette smoking behavior increases
the risk of depressive symptoms (Goodman and Capitman, 2000;
Korhonen et al., 2007, 2011) or, nicotine dependence does indeed
increase the risk of depressive symptoms (Boden et al., 2010). Second,
depression may increase the level of nicotine dependence and thus,
urge for smoking through a self-medication mechanism (Balfour and
Ridley, 2000; Royal College of Psychiatrists, 2013). A reciprocal
relation between cigarette smoking and depression has also been
reported (Breslau et al., 1998; John et al., 2004). Third, there may
be underlying factors common to both that are responsible for the
association between nicotine dependence and major depressive dis-
order. One such factor may be genetic, given that there is a genetic
component shared by both conditions (Broms et al., 2012; Korhonen
et al., 2014; Sullivan et al., 2000). It is still unclear whether smoking
ameliorates the symptoms of depression or whether depression pro-
http://dx.doi.org/10.1016/j.jad.2016.09.035
Received 27 May 2016; Received in revised form 26 August 2016; Accepted 25 September 2016
⁎ Corresponding author at: Department of Public Health, University of Helsinki, PO Box 20, FIN-00014 Helsinki, Finland.
E-mail address: tellervo.korhonen@helsinki.ﬁ (T. Korhonen).
Journal of Affective Disorders 207 (2017) 221–227
0165-0327/ © 2016 Elsevier B.V. All rights reserved.
Available online 27 September 2016
crossmark
motes nicotine addiction (Balfour and Ridley, 2000; Royal College of
Psychiatrists, 2013). The longitudinal association between smoking
and depression has been addressed in several studies (Boden et al.,
2010; Breslau et al., 1998; John et al., 2004). However, hardly any
longitudinal research has been conducted on the association between
smoking behavior and future use of prescribed antidepressant medica-
tions.
Antidepressant prescription may be used as an indicator of
depression in register based studies. Such an outcome measure is
justiﬁed because it is independent of the study investigators and of the
participation in follow-up assessments, therefore this methodological
approach is robust. The aim of the present study was to investigate
whether smoking predicts prescriptions of antidepressant medication
during 10 years’ follow-up in a large sample of twins who were
analyzed as individuals and as pairs discordant for antidepressant
medication.
2. Materials and methods
2.1. Sample
The Finnish Twin Cohort is a population based sample that is
compiled from the Central Population registry comprising all same sex
twin pairs born in Finland before 1958, who were alive in 1967. The
ﬁrst questionnaire survey of the twins was conducted in 1975 and the
second in 1981. The present study is based upon the third survey
conducted in 1990. A questionnaire was sent in 1990 to all twin pairs
born in 1930–1957, who had replied to at least one of the previous
surveys, and with both co-twins resident in Finland in 1987
(n=16,177). Among the 16,177 who had been sent the 1990 ques-
tionnaire, 12,502 responded (77.3% response rate).
The Finnish Twin Cohort was linked to the reimbursed prescrip-
tions of anti-depressants purchased from community pharmacies,
using the Prescription Register of the Finnish Social Insurance
Institute (SII). The antidepressant prescriptions of these individuals
were followed up for the 1995–2004 period (1995 was the ﬁrst year
when such data were available). Approval for the register linkages was
obtained from the Ethics committee of the Department of Public
Health, University of Helsinki and the appropriate authorities at SII.
The zygosity of the twins, monozygotic (MZ) or dizygotic (DZ), had
been determined by validated questionnaire in a previous study (Sarna
et al., 1978).
2.2. Measures
2.2.1. Outcome
The outcome variable was having register-based antidepressant
prescriptions (ATC code N06A) during years 1995–2004. The SII
prescription register was set up in 1995, and our linkage was restricted
to the end of 2004. The twins who had prescriptions were linked to the
completed questionnaire via their personal national insurance number
(assigned to each resident in Finland) as the identiﬁer. Those who had
at least four consecutive prescriptions within one year or four non-
consecutive prescriptions during the 10 years of follow-up were
considered as cases. Persons with 1–3 medication prescriptions were
excluded from the analyses. Controls were those who had no anti-
depressant prescriptions; no missing data on antidepressant prescrip-
tion existed.
The prescription register includes data on the diagnoses for which
the fully reimbursed medicines had been received. We matched the
individuals’ antidepressant prescription data with those in the 1990
survey data and deﬁned the case versus control status of the identiﬁed
individuals. Data on depressive symptoms were available from 12,063
individuals, however, there was missing information on smoking status
and/or on amount of smoking for 615 of them.
From the 12,502 persons available from the SII register, we
excluded persons with psychotic disorders or mental retardation.
Further, from the merged data set we removed individuals with other
serious chronic mental illnesses and persons who were in disability
pensions. A total of 1116 cases identiﬁed in the register data were
successfully matched with the 1990 survey data, whereas the number of
persons with no antidepressant prescription (controls) was 9968. Our
sample was restricted to those who provided data for both depression
and smoking in 1990, thus there were valid data available for the
analysis from total of 10 768 persons (1075 cases, 9693 controls).
Finally, the time-to-event analysis removed those persons who were
lost to follow-up (death or emigration) between 1990 and1994, when
the outcome events for survival analysis were started (n=116). Thus,
our time-to-event analyses were restricted to 10,652 persons (1075
cases, 9577 controls).
2.2.2. Predictor
Participants were categorized according to their baseline smoking
status as follows: 1) Never smokers (n=5174); 2) Non-daily smokers
(n=373); 3) Former smokers (n=2479); 4) Light/moderate daily
smokers, n=1785), and 5) Heavy daily smokers (n=957). The subjects
were asked if they have ever smoked more than 5–10 packs of
cigarettes (100 cigarettes) during their lifetime. Those responding
negatively were categorized as “never smokers” and were considered
as the reference group. Those responding positively were asked “Do
you smoke or have you smoked cigarettes regularly, say daily, or almost
daily during your lifetime? ” Positive responders were further asked if
they still smoked regularly. If so, they were classiﬁed as current daily
smokers. Persons who had smoked more than 100 cigarettes but were
not regular smokers were considered as non-daily smokers. Former
smokers were those regular smokers who had responded that they no
longer smoked at the time of the survey. In our data the self-reported
length of smoking abstinence among former smokers ranged mainly
between 1 and 39 years. However, there was a minor group of
participants (5.53%) who had quit smoking less than 12 months ago.
Among current daily smokers the mean daily cigarette consumption
was deﬁned. The response categories to the question “How many
cigarettes do you smoke daily on average? ” were as follows: < 5, 5–9,
10–14, 15–19, 20–24, 25–39, and > 40. Light/moderate daily smo-
kers included those smoking < 20 cigarettes/day (CPD) and heavy
daily smokers included those smoking ≥20 CPD (i.e. a pack a day).
2.2.3. Confounders
Potential confounders at the baseline included socio-demographic
background (age, gender, social class), other substance use than
smoking (binge drinking), and health status (somatic health) and these
were used to adjust the analyses. Individuals were divided into three
groups by years of education and physical activity performed during
work to determine the individual's broad socio-economic class
(Appelberg et al., 1991). Those with a minimum of 12 years of
education and sedentary work were considered “white collar”; those
with fewer than 9 years of education and ambulatory work consisting of
walking and lifting or hard physical work were “blue collar” and the
remainder formed an intermediate group of individual (Romanov et al.,
2003).
Binge drinking was deﬁned as drinking more than ﬁve bottles of
beer, or more than a bottle of wine, or more than half a bottle of spirits
on the same occasion at least once a month; only a “yes” or “no”
response was recorded (Kaprio et al., 1987).
In the 1990 questionnaire the subjects were asked if they had ever
been told by their physician that they have or have had any somatic
disease listed. The response to each item was scored 0 if ‘No’ and 1 if
‘Yes’. A Somatic Disease Index (SDI) was formed in which the subject
was considered to have ‘any somatic disease’ if in the 1990 ques-
tionnaire he/she had (i) any self-reported disease diagnosed by a
physician, or (ii) a self-reported life event of serious injury/illness, or
(iii) self-reported work disability. Other subjects were classiﬁed as
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‘healthy’. Examination of the validity of self-reported illness in a recent
population study had conﬁrmed that the agreement between ques-
tionnaire data and the individual’s medical records was very good for
well-known diseases with clear diagnostic criteria that are easily
communicated to the patient (Romanov et al., 2003). Therefore, even
after excluding persons with serious mental illnesses and disability
pensions from the 1990 data set, our analyses still included individuals
who have had any of the above mentioned somatic illnesses based on
the SDI. Thus, because these people were not excluded from the
analyses, these somatic conditions were adjusted for by using the SDI
(yes/no) as a baseline confounder.
2.2.4. Other baseline variables
Severity of depressive symptoms at baseline was assessed by the
Beck Depression Inventory (BDI) (Beck et al., 1961) in 1990. The BDI
includes 21 items, in which each statement measures the degree of
severity intensity from 0 to 3. The BDI demonstrates high internal
consistency, with alpha coeﬃcients of 0.86 and 0.81 for depressed and
non-depressed populations respectively (Beck et al., 1988). We used
the total BDI score 10 or more as a cut-oﬀ for ‘depressed’ according to
BDI guideline, whereas those with BDI score 0–9 were categorized as
“non-depressed” (Beck and Beamesderfer, 1974) to be able to stratify
the participants into depressed and non- depressed groups. When
adjusting for baseline depressiveness, we used the BDI sum score as a
continuous variable.
2.3. Statistical analysis
The twins were considered as individuals in the primary analysis.
Observations on twins within the twin pairs may be correlated. Thus,
twinship was statistically accounted for by using robust estimators of
variance and cluster option when estimating standard errors (Williams,
2000). Our study examined the associations between the smoking
status categories deﬁned above and having antidepressant prescrip-
tions (deﬁned above as no=0 or yes=1) during the 10-year follow-up
period. We used Cox Proportional Hazard Model [Hazard Ratio (HR)
and 95% Conﬁdence Interval (CI)], in order to perform time to event
analysis. P-values below 0.05 were considered to be statistically
signiﬁcant. We tested potential sex by smoking interactions on
depression medications. Data for men and women were pooled
together in the analyses because there were no signiﬁcant interactions.
Eventually, the survival analysis excluded all those persons who were
lost (died or emigrated) during the follow up. Therefore, our time-to-
event analysis was restricted to 10,652 persons (1075 cases, 9577
controls).
First, age and sex adjusted HR was calculated in order to estimate
the strength of association between baseline smoking status and having
antidepressant prescriptions in the follow-up. Next, the analysis was
adjusted for potential confounders (baseline BDI, social class, binge
drinking, somatic health). Furthermore, an incidence analysis was
conducted excluding those with at least mild baseline depressive
symptoms (BDI > 9) (n=1689) with adjustment for covariates. The
HRs indicating the associations between smoking status and antide-
pressant prescription were computed.
Finally, in order to control for familial confounding, discordant
twin pair analysis was conducted. For this, incidence analysis was
conducted among 320 discordant twin pairs (depressed case versus
non-depressed control at follow-up) where both co-twins were non-
depressed (BDI < 10) at baseline. The analyses initially disregarded
zygosity, but then those analyses were conducted separately for the MZ
and DZ twin pairs who were discordant for depression medication
(Korhonen et al., 2007) to control for genetic background. All these
analyses were adjusted also for the above mentioned confounders. All
analyses were conducted using the Stata statistical package (version
13).
3. Results
3.1. Descriptive results
There were a total of 10,768 persons (53% females) linked with the
SII registry and with valid data for these analyses. They comprised
1075 future cases and 9693 controls (i.e. no medication prescriptions).
The mean age of the participants was 44 years in both cases and
controls (Table 1). Proportion of females among the cases was 67% and
52% among the controls. Proportion of daily smokers was 30% among
the cases and 25% among the controls.
3.2. Smoking status and use of antidepressants
The results of the ﬁrst cox proportional hazard models are shown in
Table 2. Smoking status and antidepressant medication prescriptions
were signiﬁcantly associated. Those who were light or moderate, or
heavy daily smokers at the baseline had higher risk of antidepressant
medication during the follow-up period when adjusted for age and sex
compared to never smokers. When adjusted for age, sex, and baseline
BDI, heavy daily smokers (HR 1.30, 95% CI 1.03–1.64) were more
likely to have antidepressant prescriptions compared to never smokers.
Further, when adjusted for age, sex, and social class, the use of
antidepressants remained signiﬁcant among light or moderate daily
smokers (HR 1.29, 95% CI 1.09–1.53) and among heavy daily smokers
(HR 1.63, 95% CI 1.30–2.04). There was slight decrease in risk
estimates when adjusted for age, sex and binge drinking, but still light
or moderate daily smokers (HR 1.23, 95% CI 1.03–1.47) and heavy
daily smokers (HR 1.56, 95% CI 1.24–1.97), were more likely to
receive antidepressants than never smokers. These associations re-
mained signiﬁcant also after adjusting for age, sex and somatic health.
When adjusted for all the confounders simultaneously, the results no
longer remained signiﬁcant. As a post hoc test, we compared the risk
estimates of heavy daily smoking men and women in terms of
antidepressant medication but found no signiﬁcant diﬀerence, which
indicated that heavy daily smoking poses a similar risk on men and
women in terms of depression treated by medication.
Further, we obtained results that were unaﬀected by baseline
depressiveness by conducting incidence analysis on those individuals
without baseline depression i.e. those who did not have depressive
symptoms in the 1990 survey (BDI score < 10) (Table 3). When
adjusted for age and sex, light or moderate daily smokers and heavy
Table 1
Demographic characteristics of the study sample at the baseline in relation to future case
status.
Demographic
Characteristic
Total
(N=10,768)
Casesa (N=1075) Controlsb
(N=9693)
Age, years; M (SD) 43.7 (7.70) 43.6 (7.60) 43.7 (7.72)
Gender N % N %
Male 4 994 351 32.6 4643 47.9
Female 5 774 724 67.4 5050 52.1
Smoking status
Never smokers 5 174 496 46.1 4 678 48.3
Non-daily smokers 373 37 3.44 336 3.47
Former smokers 2 479 222 20.6 2 257 23.3
Light or moderate
daily smokers
1 785 212 19.7 1 573 16.2
Heavy daily
smokers
957 108 10.0 849 8.76
M=Mean.
SD=Standard Deviation
N=Total number
a Those who had at least four antidepressant prescriptions during one year or during
the 10 years of follow up.
b Those who did not have any antidepressant prescriptions.
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daily smokers had increased risk for antidepressant medication (HR
1.29, 95% CI 1.05–1.59) and (HR 1.58, 95% CI 1.20–2.08), respec-
tively. Similar results were obtained when the incidence analysis was
adjusted for other potential confounders. We found that the risk
estimates for smoking changed only marginally after adjustment of
social class, binge drinking and somatic illness compared to age and sex
adjusted results. Finally, when adjusted for all confounders simulta-
neously, the associations were robust, i.e. the estimates were for light
or moderate daily smokers (HR 1.28, 95% CI 1.03–1.58) and heavy
daily smokers (HR 1.56, 95% CI 1.17–2.08), respectively.
Within-pair analysis was conducted among twin pairs discordant
for the case control status in order to control for familial confounding
(Table 4). Survival analysis registered the actual time of the ﬁrst
antidepressant prescription among the cases. Therefore, this analysis
initially included all the concordant and discordant pairs. However, the
risk estimates were based on the informative discordant pairs only.
There were total of 320 discordant twin pairs, in which one of the twins
was a case and the other twin a control, while neither twin was
depressed at the baseline period (incidence analysis). The proportion of
pairs in which one twin was a daily smoker and had antidepressant
prescriptions while the respective co-twin was a never smoker and had
no antidepressant prescriptions was higher compared to proportion of
twin pairs where the smoking versus antidepressant condition was
reversed. The within-pair analysis revealed that current daily smoking
remained a signiﬁcant predictor (HR 1.86, 95% CI 1.09–3.18) of the
outcome. Further, when adjusted for potential confounders, this
association remained signiﬁcant. Similarly, current daily smokers
among MZ pairs (HR 1.39, 95% CI 0.43–4.48) and DZ pairs (HR
1.95, 95% CI 1.06–3.60), were at similarly elevated risk for antide-
pressants, yet the risk estimate was statistically signiﬁcant for the DZ
pairs only.
4. Discussion
Several studies relate cigarette smoking with the occurrence of
depression (Elmasry et al., 2014; Goodman and Capitman, 2000;
Korhonen et al., 2007, 2011). In this study, we aimed to investigate
whether cigarette smoking was associated with antidepressant pre-
scription over a 10 year follow-up period. We found that daily smokers
in 1990 had higher likelihood for using prescribed antidepressant
medication during the 1995–2004 period. Our ﬁndings are in line with
the previously found association between smoking and self-reported
depressive symptoms within the same twin cohort (Korhonen et al.,
2007).
The mean age of the participants in this study was 44 years at the
time when the smoking behavior was assessed. Thus, our sample
represents adult twin population in Finland. A study conducted in the
US among the teenagers who were not depressed during the baseline,
found that cigarette smoking was the strongest predictor of developing
depressive symptoms over a one year of follow-up (Goodman and
Capitman, 2000). That suggests that smoking and depression can be
associated – not only in adults - but already at an early age.
Depression is twice more common among women than in men
(Kessler, 2003). This is also reﬂected in our study where twice as many
cases among women compared to men were observed. The question is,
whether the association between smoking and depression is diﬀerent
between men and women. Previous studies reported that women who
smoked were at higher risk of depression than men, suggesting that
smoking may pose higher risk for women (Husky et al., 2008; Royal
College of Psychiatrists, 2013). However, in our sample, we did not see
any signiﬁcant sex by smoking –interaction. Thus, we did not analyze
men and women separately. We also tested the diﬀerence in the risk
estimates of heavy daily smoking men and women in terms of use of
antidepressants. We did not ﬁnd statistically signiﬁcant diﬀerence,
indicating that in our sample heavy smoking poses a similar risk among
men and women in terms of depression treated by antidepressantTa
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medication.
We found that light/moderate and heavy daily smokers had a
higher likelihood for use of antidepressants in the follow-up compared
to never smokers, when adjusted for age and sex. Heavy daily smokers
had a two-fold risk for antidepressants over never smokers. However,
non-daily and former smokers did not show any signiﬁcant association
for antidepressant medication use in the follow-up. This ﬁnding may
reﬂect a dose-relationship between smoking and depression. A pre-
vious study based on earlier surveys in the same twin cohort, found
that persistent smoking increased the risk for BDI-deﬁned depression
but former smoking did not signiﬁcantly elevate the risk for later
depression across depression dimensions (Korhonen et al., 2011)
which is in line with our ﬁndings.
Our results are supported also by the ﬁndings from a cross sectional
Finnish study, which showed that current smoking was signiﬁcantly
associated with antidepressant treatment among both men and women
(Laukkala et al., 2001). In our study, former smokers did not show any
signiﬁcant association, however, in a meta-analysis, quitting smoking
was associated with reduced depression and improved quality of life
compared to continuing smoking (Taylor et al., 2014). However,
another study showed no signiﬁcant change in depression level
between those who had quit and those who remained smokers
(Kinnunen et al., 2006).
In our study, the incidence analysis among those who were not
depressed at the baseline, the risk estimates for smoking changed only
slightly after adjustment for socio-demographic confounders, somatic
illnesses and binge drinking. Even when adjusted for all the confoun-
ders simultaneously, the results remained similar. Thus, the eﬀect of
smoking seems to be robust. Our previous study also showed similar
results, speciﬁcally: persistent smoking was associated with higher risk
of depression among men, even after adjustment of socio-demographic
and other confounders (Korhonen et al., 2007). Such confounders
should be considered because they might contribute to the associations
between predictor and outcome variables. For example, excessive use
of alcohol has been related with depressive symptoms (Davidson,
1995), and somatic illness can also increase vulnerability to depression
(Romanov et al., 2003) while both are associated with smoking.
Our ﬁndings can be discussed according to diﬀerent assumptions:
First, nicotine addiction among current smokers might increase the
probability of depressive states or depression medication use. The main
body of our results supports this hypothesis. This “addiction hypoth-
esis” is also in line with our ﬁnding about alcohol drinking because
binge drinkers were more likely to use antidepressants than non-binge
drinkers (data not shown). However, there may be alternative inter-
Table 3
Hazard Ratios for having antidepressant medication prescriptions by smoking status in 1990 among persons without baseline depression.
Smoking status Model Ia Model IIb Model IIIc Model IVd Model Ve
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Never smokers 1.00 1.00 1.00 1.00 1.00
Non-daily smokers 1.01 0.66–1.55 0.958 1.01 0.66–1.54 0.971 1.03 0.67–1.58 0.889 1.02 0.67–1.57 0.913 1.04 0.68–1.60 0.847
Former smokers 1.16 0.95–1.40 0.137 1.15 0.95–1.40 0.143 1.14 0.94–1.40 0.190 1.13 0.93–1.37 0.203 1.11 0.91–1.36 0.295
Light or moderate daily smokers 1.29 1.05–1.59 0.014 1.31 1.07–1.61 0.010 1.29 1.04–1.60 0.019 1.27 1.03–1.56 0.024 1.28 1.03–1.58 0.025
Heavy daily smokers 1.58 1.20–2.08 0.001 1.60 1.21–2.11 0.001 1.61 1.21–2.15 0.001 1.50 1.14–1.98 0.004 1.56 1.17–2.08 0.003
HR=Hazard Ratio, CI=Confidence Interval, P=P-Value
a Adjusted for age and sex.
b Adjusted for age, sex and social class.
c Adjusted for age, sex and binge drinking.
d Adjusted for age, sex and somatic health.
e Adjusted for age, sex, social class, binge drinking and somatic health simultaneously.
Table 4
Discordant twin pair analyses for having antidepressant medication prescriptions by smoking status in 1990 among those without baseline depression.
Smoking status Model I Model IIb Model IIIc Model IVd Model Ve
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
All (N=320 pairs)
Never smokers 1.00 1.00 1.00 1.00 1.00
Non-daily smokers 1.60 0.54–4.72 0.394 1.61 0.54–4.77 0.387 1.65 0.56–4.89 0.366 1.61 0.54–4.78 0.389 1.67 0.56–5.00 0.358
Former smokers 1.38 0.81–2.34 0.241 1.38 0.81–2.35 0.239 1.42 0.81–2.48 0.220 1.33 0.78–2.28 0.296 1.36 0.77–2.39 0.290
Daily smokersa 1.86 1.09–3.18 0.023 1.86 1.09–3.18 0.023 2.10 1.19–3.73 0.011 1.77 1.02–3.06 0.040 1.98 1.11–3.54 0.021
Monozygotic (N=87 pairs)
Never smokers 1.00 1.00 1.00 1.00 1.00
Non-daily smokers NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Former smokers 0.54 0.18–1.60 0.266 0.54 0.18–1.61 0.271 0.57 0.18–1.77 0.331 0.54 0.18–1.60 0.265 0.54 0.17–1.71 0.296
Daily smokersa 1.39 0.43–4.48 0.583 1.37 0.42–4.45 0.597 1.95 0.55−6.97 0.303 1.36 0.41−4.60 0.616 1.78 0.48−6.55 0.387
Dizygotic (N=230 pairs)
Never smokers 1.00 1.00 1.00 1.00 1.00
Non-daily smokers 1.32 0.41−4.25 0.643 1.33 0.41−4.29 0.634 1.34 0.41−4.34 0.627 1.35 0.42−4.40 0.614 1.38 0.42−4.54 0.593
Former smokers 1.94 1.02−3.68 0.042 1.94 1.02−3.68 0.042 2.01 1.02–3.97 0.043 1.88 0.98−3.57 0.055 1.93 0.97−3.84 0.060
Daily smokersa 1.95 1.06−3.60 0.032 1.95 1.06–3.60 0.032 2.02 1.06–3.88 0.034 1.86 1.00−3.46 0.051 1.92 0.99−3.72 0.052
NA=Not Accessible (very few observations) HR=Hazard Ratio, CI=Confidence Interval,
a Including light, moderate or heavy daily smokers.
b Adjusted for social class.
c Adjusted for binge drinking.
d Adjusted for somatic health.
e Adjusted for social class, binge drinking & somatic health simultaneously.
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pretations. For example, living free of depression may have increased a
smoker's self-eﬃcacy to quit smoking, i.e. non-depressed subjects are
more likely to quit smoking than depressed patients (Killen et al.,
2003). Finally, living with depression can increase the risk of smoking
through a self-medication mechanism (Balfour and Ridley, 2000; Royal
College of Psychiatrists, 2013). Thus, this can further explain why
depressed patients are more likely to use tobacco to obtain nicotine.
However, ascertaining which of these alternative assumptions is
correct or whether they both apply is beyond the scope of this study.
When we controlled for familial and genetic background using
discordant twin pairs, smoking status remained a predictor of sub-
sequent antidepressant use, although the association was not statisti-
cally signiﬁcant for MZ pairs. Such analyses of MZ and DZ pairs
suggest that having antidepressant prescriptions is essentially related
to smoking and not to shared genetic background, but the analysis of
MZ pairs may lack statistical power. This ﬁnding is also supported by
our previous study ﬁnding where both MZ pairs and DZ pairs showed
increased risk for self-reported depressive symptoms among persistent
smokers and also among quitters (Korhonen et al., 2007).
Our ﬁndings demonstrate that daily smoking may be associated
with future depression, which is reﬂected in the need for antidepres-
sant treatment. This may be the case particularly when depression is
severe or moderately severe, and antidepressant medication is required
(National Collaborating Centre for Mental Health, 2010). Cigarette
smoking leads often to nicotine dependence, and individuals with
nicotine dependence have a higher likelihood for lifetime major
depressive disorder, while certain neurochemical mechanisms are
suggested to be responsible for this association (Balfour and Ridley,
2000).
4.1. Strengths and limitations
The main strength of the study is the use of register based data on
antidepressant prescriptions, which excludes the confounding eﬀects of
recall bias and lack of participation in follow-up surveys. Using register
data as a proxy indicator of depression may also be considered as a
limitation, although purchasing antidepressant medication is objective
evidence that was available for all participants in the 10 years follow-up
survey. However, mild depression is not necessarily treated by pre-
scribed medications, which implies that the register based outcome in
our study may represent only the more severe depression cases.
Second, this population-based cohort was followed-up and reported
15 years later and provides reliable data on long-term eﬀects of
smoking on the use of antidepressants. Third, the analyses were
adjusted for several potential confounders. In addition, within-pair
analysis in this genetically informative sample was applied to twin pairs
discordant for the case-control status in order to control familial and
genetic confounding.
We acknowledge the limitation that although antidepressants are
mainly used for treating depression, they are also used in the treatment
of other mental disorders (Sadock and Sadock, 2008), which may cause
some clinical heterogeneity in our sample. However, when antidepres-
sants are used, depression is most probably also present at least as a
comorbid condition. Another limitation is that the register-based
information of antidepressant prescriptions was used as the proxy of
quantifying the numbers suﬀering from depression. Thus, among the
controls, who did not have antidepressant prescriptions, there may
have been individuals with depressive symptoms without seeking
medical attention. However, this probable depression has supposedly
been mild. A further limitation of this study is that we were not able to
fully test the possibility of reciprocal relationships between smoking
and antidepressant medication. Speciﬁcally, it may be argued that
although smoking leads to increased likelihood of depression and
consequently antidepressant medication, the use of medication may
reduce both depression and smoking. Unfortunately, in this study we
could not test the reverse causal association, i.e. whether depression
predicts smoking. A further limitation is that we could only use the
1990 smoking status in this analysis and could not take into account
changes in smoking status after the baseline assessment. However,
because our data include middle age to older adults, the option of
smoking initiation would not be issue of concern here. However, we
acknowledge that smoking cessation after 1990 would be an issue of
concern and thus, we consider this as a limitation.
We conclude that daily cigarette smoking predicts antidepressant
medication, even when controlling for essential confounders and
familial factors. This study highlights the need of carefully and
systematically assessing smoking behavior among the patients suﬀer-
ing from or being at risk for developing depressive symptoms.
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